Skip Navigation

JNCI Monographs 2003 2003(31):41-46;
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Palefsky, J. M.
Right arrow Articles by Holly, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palefsky, J. M.
Right arrow Articles by Holly, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute Monographs, No. 31, 41-46, 2003
© 2003 Oxford University Press

ARTICLE

Chapter 6: Immunosuppression and Co-infection with HIV

Joel M. Palefsky, Elizabeth A. Holly

J. M. Palefsky, M.D., C.M., F.R.C.P.(C), University of California, 505 Parnassus Ave., Rm. M1203, Box 0126, San Francisco, CA 94143 (e-mail: joelp{at}medicine.ucsf.edu); E. A. Holly, Ph.D., M.P.H., University of California, Laurel Heights Suite 280, San Francisco, CA 94143 (e-mail: eaholly{at}itsa.ucsf.edu).

Individuals with immunosuppression caused by HIV infection or organ transplantation are at increased risk of human papillomavirus (HPV)-associated anogenital cancers compared with age-matched healthy individuals. The exact role of immunosuppression in conferring increased risk is not known. Although it is unknown which stages of progression from dysplasia to cancer are most affected by immunosuppression, current data suggest that immunosuppression is most strongly associated with the early stages of dysplasia, and that progression to cancer per se is not associated with immunosuppression. Studies to determine this relationship in detail are hampered by the paucity of precise biomarkers of cell-mediated immune response to HPV. This chapter will address these and other issues to provide a better understanding of the biology of HPV infection among immunocompromised individuals. Questions remain about the biology of HPV infection among immunocompromised HIV-negative individuals (e.g., transplant patients) compared with those who are HIV-positive; the impact of highly active antiretroviral therapy on the natural history of anogenital dysplasia and cancer among those who are HIV-positive, and whether the biology of specific HPV types is the same in HIV-positive as in HIV-negative individuals. Understanding HPV infection in those who are immunocompromised offers the potential to better understand its pathobiology in the putatively immunocompetent host.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int J STD AIDSHome page
S. Asiimwe, C. C Whalen, D. J Tisch, E. Tumwesigye, and A. K Sethi
Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda
Int J STD AIDS, September 1, 2008; 19(9): 605 - 610.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
J. B. Liao, J. Publicover, J. K. Rose, and D. DiMaio
Single-Dose, Therapeutic Vaccination of Mice with Vesicular Stomatitis Virus Expressing Human Papillomavirus Type 16 E7 Protein
Clin. Vaccine Immunol., May 1, 2008; 15(5): 817 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Int J STD AIDSHome page
A Pereira, H R Lacerda, and R R Barros
Prevalence and factors associated with anal lesions mediated by human papillomavirus in men with HIV/AIDS
Int J STD AIDS, March 1, 2008; 19(3): 192 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
A. Kreuter, N. H. Brockmeyer, S. J. Weissenborn, A. Wafaisade, H. Pfister, P. Altmeyer, U. Wieland, and for the German Competence Network HIV/AIDS
5% Imiquimod Suppositories Decrease the DNA Load of Intra-anal HPV Types 6 and 11 in HIV-Infected Men After Surgical Ablation of Condylomata Acuminata.
Arch Dermatol, February 1, 2006; 142(2): 243 - 244.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.